Kyntra Bio develops cancer and anemia treatments, including a prostate cancer drug candidate and roxadustat, from San Francisco. KYNB reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for KYNB are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in KYNB in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYNB is in one of them and how their past KYNB trades turned out.
Kyntra Bio is a biopharmaceutical company in San Francisco, California, that develops treatments for cancer and anemia. Its lead program, FG-3246, is a drug candidate for advanced prostate cancer, paired with FG-3180, an imaging agent that helps identify suitable patients. The company also holds rights to roxadustat, a treatment for anemia in patients with chronic kidney disease, and is developing it for a blood disorder called myelodysplastic syndromes.
